## Abstract ## Introduction Memantine is currently the only treatment approved for moderately severe to severe Alzheimer's disease (AD). There is still some discussion as to its place in clinical practice and many UK clinicians are discouraged for economic reasons from prescribing it. We adopt a β
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
β Scribed by Michael A. Rogawski; Gary L. Wenk
- Book ID
- 109105625
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 519 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1080-563X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Since it has become evident that increased oxidative stress is involved in the pathogenesis of Alzheimer's disease, the therapeutical use of antioxidants has been discussed. To date there are several studies showing that lipid peroxidation in particular is increased not only in brain ti
There is increasing evidence for the involvement of glutamate-mediated neurotoxicity in the pathogenesis of Alzheimer's disease (AD). We suggest that glutamate receptors of the N-methyl-D-aspartate (NMDA) type are overactivated in a tonic rather than a phasic manner in this disorder. This continuous